Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial
Journal of Clinical Oncology · 10.04.2025 · 43 (11) · 1279-1288
DOI: 10.1200/jco-24-02266 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.04.2025. Verfasst von Elias K Mai und 38 weiteren Autor:innen. Beteiligte Einrichtung: Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg University, H…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Hematopoietic Stem Cell Transplantation, Multiple Myeloma. Die Arbeit wurde bisher 81-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Previously, addition of isatuximab (Isa) to standard-of-care lenalidomide-bortezomib-dexamethasone (RVd) in transplant-eligible patients with newly diagnosed multiple myeloma in the GMMG-HD7 trial (ClinicalTrials.gov identifier: NCT03617731 ) resulted in a significant increase of minimal residual disease negativity (MRD–) rates after induction therapy. A total of 662 patients were randomly assigned to receive induction therapy with Isa-RVd (n = 331) or RVd (n = 329), followed by single or tandem autologous stem-cell transplant and second random assignment to maintenance with lenalidomide alone or Isa-lenalidomide. We report updated results for part 1 from first random assignment to post-transplant. As of January 31, 2024, MRD– rates continued to deepen after transplant (66% Isa-RVd v 48% RVd). Isa-RVd induction therapy significantly prolonged progression-free survival (PFS) compared with RVd regardless of maintenance therapy (hazard ratio, 0.70 [95% CI, 0.52 to 0.95]; P = .0184). Weighted risk set estimator analysis accounting for second random assignment followed by maintenance with only lenalidomide confirmed a statistically significant benefit for Isa-RVd followed by lenalidomide maintenance versus RVd followed by lenalidomide maintenance (stratified weighted log-rank test P = .016). In conclusion, after 18-week induction therapy followed by transplant without consolidation therapy, adding Isa to RVd resulted in a significant PFS benefit, regardless of maintenance strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
- National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany.
- Division of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany.
- Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.
- Department of Internal Medicine II, University Hospital Tübingen, Tübingen, Germany.
- Department for Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany.
ORCID-Profile: Elias K Mai, Uta Bertsch, Roland Fenk, Roland Schroers, Christoph Mann, Lisa B Leypoldt, Christof Scheid, Steffen Luntz, Niels Weinhold, Tobias A W Holderried, Karolin Trautmann-Grill, Evgenii Shumilov, Christian S Michel, Marc S Raab, Axel Benner, Katja C Weisel, Hans J Salwender, Hartmut Goldschmidt
Zitieren
APA
Mai, E. K., Bertsch, U., Pozek, E., Fenk, R., Besemer, B., Hanoun, C., Schroers, R., von Metzler, I., Hänel, M., Mann, C., Leypoldt, L. B., Heilmeier, B., Huhn, S., Vogel, S. K., Hundemer, M., Scheid, C., Blau, I. W., Luntz, S., Weinhold, N., …, & German-speaking Myeloma Multicenter Group (GMMG) HD7 (2025). Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial. Journal of Clinical Oncology, 43(11), 1279-1288. https://doi.org/10.1200/jco-24-02266
Vancouver
Mai EK, Bertsch U, Pozek E, Fenk R, Besemer B, Hanoun C, et al. Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial. Journal of Clinical Oncology. 2025;43(11):1279-1288. doi:10.1200/jco-24-02266
BibTeX
@article{Mai2025,
author = {Mai, Elias K and Bertsch, Uta and Pozek, Ema and Fenk, Roland and Besemer, Britta and Hanoun, Christine and Schroers, Roland and von Metzler, Ivana and Hänel, Mathias and Mann, Christoph and Leypoldt, Lisa B and Heilmeier, Bernhard and Huhn, Stefanie and Vogel, Sabine K and Hundemer, Michael and Scheid, Christof and Blau, Igor W and Luntz, Steffen and Weinhold, Niels and Tichy, Diana and Holderried, Tobias A W and Trautmann-Grill, Karolin and Gezer, Deniz and Klaiber-Hakimi, Maika and Müller, Martin and Shumilov, Evgenii and Knauf, Wolfgang and Michel, Christian S and Geer, Thomas and Riesenberg, Hendrik and Lutz, Christoph and Raab, Marc S and Benner, Axel and Hoffmann, Martin and Weisel, Katja C and Salwender, Hans J and Goldschmidt, Hartmut and German-Speaking Myeloma Multicenter Group (GMMG) HD7 Investigators, German-Speaking Myeloma Multicenter Group (GMMG) HD7 Investigators and German-speaking Myeloma Multicenter Group (GMMG) HD7, German-speaking Myeloma Multicenter Group (GMMG) HD7},
title = {Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {11},
pages = {1279--1288},
doi = {10.1200/jco-24-02266}
}
EUVIMED